Feds License Protein That Skips Chemo for Stem Cell Transplants
Published Date: 9/23/2026
Notice
Summary
The government is offering a new invention for licensing that makes stem cell transplants safer and less harsh, especially for leukemia patients and older folks. This tech uses a special protein to prepare patients for transplants without the tough side effects of chemo and radiation. Companies can start licensing this preclinical innovation now to help bring better treatments to market faster.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Safer stem-cell transplant conditioning
The NIH is offering patent rights for a preclinical therapy (DT390-biscFV(cMPL)) that can be used as a new conditioning regimen to make hematopoietic stem and progenitor cell (HSPC) transplants safer, especially for leukemia patients and older people who cannot tolerate chemo or radiation. The notice says the technology limits chemotherapeutic cytotoxicity, better penetrates bone marrow, has a short half-life, and has in vivo (animal) data available.
Licensing and collaboration chance for developers
The government is making patent rights available for licensing and commercial development for the DT390-biscFV(cMPL) technology (HHS Ref. No.: E-188-2021-0) and is seeking statements of capability or interest for collaborative research to further develop, evaluate, or commercialize it. Licensing contact and a collaborative research contact are provided so companies and research groups can begin discussions now; a signed Confidential Disclosure Agreement may be required to get unpublished information.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-19303, Submission for OMB review; 30-Day Comment Request; the Impact and Costs of Promoting Objectivity in Research 42 CFR Part 50 Subpart F and Responsible Prospective Contractors 45 CFR Part 94 (Office of the Director)
The National Institutes of Health (NIH) is asking for your thoughts on how they collect info to keep research honest and fair. This affects researchers and contractors who work with NIH, aiming to make sure everything stays clear and trustworthy. You’ve got until October 22, 2026, to share your comments—no cost changes, just a check-in to keep things running smoothly!
2026-19155, Proposed Collection; 60-Day Comment Request; PHS Applications and Pre-Award Reporting Requirements (OD)
The NIH is updating how researchers submit their Public Health Service applications and reports before awards, starting May 25, 2026. This change aims to make data management clearer and easier, affecting anyone applying for NIH funding. They want your feedback by November 17, 2026, to help improve the process without adding extra hassle or costs.
2026-19156, Proposed Collection; 60-Day Comment Request; Post-Award Reporting Requirements Including Research Performance Progress Report (OD)
The National Institutes of Health (NIH) wants your thoughts on updating how researchers report their progress after getting awards. This affects anyone who receives NIH funding and aims to make reporting clearer and less of a hassle. Comments are due by November 17, 2026, so don’t miss your chance to weigh in!
2026-18937, Proposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form (Office of the Director/Office of Intramural Research)
The NIH is rolling out a new online form to make reporting research cheating easier and fairer. Anyone involved with NIH research can use this form to report problems like lying or copying, even anonymously. They want your feedback by November 16, 2026, to make sure the form works well without causing extra hassle.
2026-18877, Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of HPV 16 E6-Expressing Cancers
The National Cancer Institute plans to give MedGene Therapeutics an exclusive license to develop and sell special engineered cell treatments for cancers caused by HPV 16 E6. This means MedGene will have the sole right to use these inventions, potentially speeding up new cancer therapies. If you want to comment or apply for a license, you must do so by September 30, 2026.
2026-18646, Draft NIH Biosafety Policy for Research Involving Biohazards
The NIH is updating its biosafety rules to keep research safe as science changes and grows. This new policy will replace old guidelines and affect anyone working with biohazards in NIH-funded research. They want your thoughts by October 19, 2026, to help shape these important safety updates without adding extra costs.
Previous / Next Documents
Previous: 2026-19427, Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of Previously Approved Collection; Petition for Commutation of Sentence
The Department of Justice’s Office of the Pardon Attorney is updating its form for people asking to shorten their prison sentences. They want your feedback on how easy the form is to use and how much time it takes to fill out. Comments are open for 30 days, and this update aims to make the process smoother and less time-consuming for everyone involved.
Next: 2026-19432, Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Previously Approved Collection; Title-Procurement Quota Certification and Recordkeeping Requirements
The DEA wants to keep collecting info from people who handle certain controlled substances to make sure they follow rules about how much they can get and keep. They’re asking for your thoughts on this paperwork for the next 60 days, until November 23, 2026. This won’t cost extra money but helps keep things clear and fair for everyone involved.